Article |

Neonatal Herpetic Infection:  Report of Two Premature Infants Treated With Systemic Use of Idoxuridine

Gordon A. Tuffli, MD; Andre J. Nahmias, MD
Am J Dis Child. 1969;118(6):909-914. doi:10.1001/archpedi.1969.02100040911018.
Text Size: A A A
Published online

ALTHOUGH the prognosis in herpes simplex encephalitis remains unclear in view of problems inherent in providing laboratory confirmation of diagnoses,1 reports in current literature2-8 indicate the disease is severe, often fatal, frequently leaving survivors with neurological sequelae.

Until recently, treatment consisted largely of supportive care, with occasional administration of γ-globulin or hyperimmune plasma. During the past three years, several authors described beneficial results in herpes simplex encephalitis with systemic use of idoxuridine (5-iodo-2′-deoxyuridine).8-13 However, no one has reported experience with systemic use of idoxuridine in the premature infant. Partridge and Millis14 used intravenously administered idoxuridine in a combined, five-day course of intermittent and continuous infusion in a newborn term infant with systemic herpes simplex. The infant received a total dose of 580 mg/kg and showed clinical improvement, with no toxicity noted. The infant died later, probably from the effect of secondary bacterial infection.

This report presents


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.